$2.90
5.45% today
NYSE, Aug 18, 10:16 pm CET
ISIN
US67080N1019
Symbol
NUVB

Nuvation Bio Inc - Ordinary Shares - Class A Stock price

$2.75
+0.62 29.11% 1M
+0.48 21.15% 6M
+0.09 3.38% YTD
+0.00 0.00% 1Y
-0.33 10.71% 3Y
-7.25 72.50% 5Y
-7.25 72.50% 10Y
-7.25 72.50% 20Y
NYSE, Closing price Fri, Aug 15 2025
-0.01 0.36%
ISIN
US67080N1019
Symbol
NUVB
Industry

Key metrics

Basic
Market capitalization
$938.9m
Enterprise Value
$482.9m
Net debt
positive
Cash
$461.7m
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
65.4 | 60.0
EV/Sales
33.6 | 30.9
EV/FCF
negative
P/B
2.2
Financial Health
Equity Ratio
85.8%
Return on Equity
-122.5%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$14.4m | $15.7m
EBITDA
$-223.6m | -
EBIT
$-224.6m | $-248.6m
Net Income
$-202.9m | -
Free Cash Flow
$-168.6m
Growth (TTM | estimate)
Revenue
897.2% | 98.9%
EBITDA
-99.2% | -
EBIT
-99.3% | -48.4%
Net Income
60.3% | -
Free Cash Flow
-100.1%
Margin (TTM | estimate)
Gross
27.5%
EBITDA
-1,557.6% | -
EBIT
-1,564.9%
Net
-1,413.4% | -
Free Cash Flow
-1,174.4%
More
EPS
$-0.6
FCF per Share
-
Short interest
33.3%
Employees
220
Rev per Employee
$40.0k
Show more

Is Nuvation Bio Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Nuvation Bio Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Nuvation Bio Inc - Ordinary Shares - Class A forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Nuvation Bio Inc - Ordinary Shares - Class A forecast:

Buy
92%
Hold
8%

Financial data from Nuvation Bio Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
14 14
897% 897%
100%
- Direct Costs 10 10
670% 670%
72%
3.95 3.95
4,289% 4,289%
28%
- Selling and Administrative Expenses 120 120
225% 225%
833%
- Research and Development Expense 109 109
43% 43%
759%
-224 -224
99% 99%
-1,557%
- Depreciation and Amortization 1.05 1.05
156% 156%
7%
EBIT (Operating Income) EBIT -225 -225
99% 99%
-1,564%
Net Profit -203 -203
60% 60%
-1,413%

In millions USD.

Don't miss a Thing! We will send you all news about Nuvation Bio Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nuvation Bio Inc - Ordinary Shares - Class A Stock News

Positive
The Motley Fool
11 days ago
NUVB Sales Jump 1,043% on Drug Launch
Neutral
Business Wire
11 days ago
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “With FDA approval of IBTROZI, we're proud of our swift evolution into a commercial‐stage company executing across functions to deliver a dif...
Neutral
Business Wire
13 days ago
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data will be presented at the IASLC 2025 World Conference on Lung Cancer (WCLC) taking place September 6–9, 2025 in Barcelona, Spain, and the European Society of Medical Oncology Congress Meeting (ESMO) October 17–...
More Nuvation Bio Inc - Ordinary Shares - Class A News

Company Profile

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Head office United States
CEO David Hung
Employees 220
Founded 2018
Website www.nuvationbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today